Stone Clinical Laboratories, LLC

Stone Clinical Laboratories, LLC, based in the US, provides advanced molecular diagnostic services, focusing on viral screening and detection through its state-of-the-art PCR technology, catering to both individual patients and healthcare providers. Founded in 2016 and headquartered in Walton, US, Stone Clinical Laboratories specializes in molecular diagnostics. The company's operations have evolved to focus on providing accessible lab testing services to a diverse clientele, including healthcare providers and patients. The founder has not been disclosed, and the company operates independently without known parent or subsidiary companies.

In 2025, the company was acquired by Fibronostics US, Inc. for an undisclosed amount, marking a strategic shift in its business operations. Stone Clinical Laboratories has completed a total of one deal to date, with the most recent deal occurring on October 27, 2025. STONE Diagnostics specializes in comprehensive molecular diagnostic services, offering advanced PCR technology as its core product for viral screening and detection.

The company caters to traditional healthcare settings and individuals seeking lab tests independently, improving accessibility and convenience in diagnostics. Their offerings include personalized service from sample collection to customized reporting and result delivery, enhancing the user experience. STONE serves healthcare providers, patients, and managed care organizations, with a commitment to in-network rates. Operating across multiple geographical markets, the company aims to cover over 200 million lives under its network.

Revenue generation for STONE Diagnostics is based on partnerships with healthcare providers and managed care organizations, allowing them to offer in-network pricing for diagnostic tests. Transactions typically involve direct billing to insurance companies, streamlining payments for patients. The company offers competitive rates, focusing on affordability while maintaining high testing standards. Their revenue model reflects a commitment to patient-centered care, enabling access to essential diagnostic services without unexpected costs.

Leveraging their CAP-accredited status and advanced technology, STONE Diagnostics positions itself as a key player in the molecular diagnostics market, enhancing satisfaction for both providers and patients. Following its acquisition by Fibronostics US, Inc. in October 2025, Stone Clinical Laboratories plans to utilize the new funding to expand its U. S.

laboratory operations and accelerate research programs targeting liver and metabolic disease diagnostics. The company is expected to enhance its product offerings and explore new geographic regions, although specific markets for expansion have not been disclosed.